Sulanemadlin Active Not Recruiting Phase 1 Trials for Unresectable Malignant Solid Neoplasm / metastatic Malignant Solid Neoplasms / Recurrent Breast Carcinoma / Estrogen Receptor Positive / Anatomic Stage III Breast Cancer AJCC v8 / HER2 negative / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Advanced Malignant Solid Tumor / Anatomic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / TP53 wt Allele / Anatomic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 Treatment

Indications	Status	Purpose	Phase
DBCOND0110416 (Unresectable Malignant Solid Neoplasm) DBCOND0153815 (metastatic Malignant Solid Neoplasms) DBCOND0030216 (Recurrent Breast Carcinoma) DBCOND0031389 (Estrogen Receptor Positive) DBCOND0109625 (Anatomic Stage III Breast Cancer AJCC v8) DBCOND0024919 (HER2 negative) DBCOND0109637 (Prognostic Stage IIIB Breast Cancer AJCC v8) DBCOND0109635 (Prognostic Stage III Breast Cancer AJCC v8) DBCOND0109627 (Anatomic Stage IIIB Breast Cancer AJCC v8) DBCOND0089276 (Advanced Malignant Solid Tumor) DBCOND0109626 (Anatomic Stage IIIA Breast Cancer AJCC v8) DBCOND0109638 (Prognostic Stage IIIC Breast Cancer AJCC v8) DBCOND0082200 (TP53 wt Allele) DBCOND0109628 (Anatomic Stage IIIC Breast Cancer AJCC v8) DBCOND0109636 (Prognostic Stage IIIA Breast Cancer AJCC v8)	Active Not Recruiting	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT03725436	ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors	Paclitaxel (DB01229) Sulanemadlin (DB17285)